Biotech Values

[DewDiligence]

NVS’ 177Lu-PSMA-617 hits primary endpoints in CRPC:

https://www.globenewswire.com/news-release/2021/03/23/2197317/0/en/Novartis-announces-positive-result-of-phase-III-study-with-radioligand-therapy-177Lu-PSMA-617-in-patients-with-advanced-prostate-cancer.html

Novartis today reported the first interpretable results of the Phase III VISION study evaluating the efficacy and safety of 177Lu-PSMA-617, a targeted radioligand therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared to best standard of care alone. The trial met both primary endpoints of overall survival and radiographic progression-free survival…

Further details will be presented at an unspecified medical conference.